Effects of intravenous dimethyl sulfoxide on ischemia evolution in a rat permanent occlusion model Academic Article uri icon


MeSH Major

  • Brain Ischemia
  • Dimethyl Sulfoxide
  • Infarction, Middle Cerebral Artery
  • Neuroprotective Agents


  • Dimethyl sulfoxide (DMSO) has a variety of biological actions that suggest efficacy as a neuroprotectant. We (1) tested the neuroprotective potential of DMSO at different time windows on infarct size using 2,3,5-triphenyltetrazolium staining and (2) investigated the effects of DMSO on ischemia evolution using quantitative diffusion and perfusion imaging in a permanent middle cerebral artery occlusion (MCAO) model in rats. In experiment 1, DMSO treatment (1.5 g/kg intravenously over 3 h) reduced infarct volume 24 h after MCAO by 65% (P<0.00001) when initiated 20 h before MCAO, by 44% (P=0.0006) when initiated 1 h after MCAO, and by 17% (P=0.11) when started 2 h after MCAO. Significant infarct reduction was also observed after a 3-day survival in animals treated 1 h after MCAO (P=0.005). In experiment 2, treatment was initiated 1 h after MCAO and maps for cerebral blood flow (CBF) and apparent diffusion coefficient (ADC) were acquired before treatment and then every 30 mins up to 4 h. Cerebral blood flow characteristics and CBF-derived lesion volumes did not differ between treated and untreated animals, whereas the ADC-derived lesion volume essentially stopped progressing during DMSO treatment, resulting in a persistent diffusion/perfusion mismatch. This effect was mainly observed in the cortex. Our data suggest that DMSO represents an interesting candidate for acute stroke treatment.

publication date

  • August 2005



  • Academic Article



  • eng

PubMed Central ID

  • PMC2949963

Digital Object Identifier (DOI)

  • 10.1038/sj.jcbfm.9600095

PubMed ID

  • 15744247

Additional Document Info

start page

  • 968

end page

  • 77


  • 25


  • 8